Julie Lellouche, Author at Labiotech.eu

About

Blogger for Labiotech.eu. Entrepreneurial Student at SupBiotech, Paris Higher Biotechnology Institute.

Articles by Julie Lellouche

News and Trends 18 Apr 2015

Another Partnership between Immunocore and MedImmune against Skin Cancer

Immunocore Limited, a world-leading biotechnology company developing novel biological drugs to treat cancer and other diseases, and MedImmune, the global biologics research and development arm of AstraZeneca have just entered into a second effective collaboration for a potential skin cancer treatment. It concerns melanoma which is a form of skin cancer that accounts for less than five per cent of […]

April 18, 2015 - 2 minutesmins - By Julie Lellouche

News and Trends 11 Apr 2015

Cardio3 Biosciences Embedded BioLife Solutions for a Heart Regenerative Therapy

Cardio3 BioSciences is again on the front page of biotech news. After announcing the launching of an IPO on Nasdaq and getting an US patent, the company has now embedded the BioLife Solutions‘ clinical grade CryoStor cryopreservation freeze media, in its ongoing Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1) phase III clinical trial in Europe and Israel and the pending CHART-2 phase III clinical trial […]

April 11, 2015 - 2 minutesmins - By Julie Lellouche

News and Trends 4 Apr 2015

An Exclusive Agreement Supporting Patients Requiring Access to an Intravenous Nutritional Therapy

April 4, 2015 - 0 minutesmins - By Julie Lellouche

News and Trends 28 Mar 2015

Strategic Partnership Between Green Cross and Nanolek

The South Korean biopharmaceutical company Green Cross and the Russian pharmaceutical company Nanolek signed a strategic partnership agreement for the commercialisation of Green Cross’ biologics in the Russian market. Green Cross provides healthcare solutions that address the evolving needs of human health. The company is specialised in the development and manufacturing of plasma-derivatives, vaccines and recombinant […]

March 28, 2015 - 2 minutesmins - By Julie Lellouche

News and Trends 20 Mar 2015

Let’s Focus on Calypso Biotech, a New Promising Startup that Concentrates on Niche Gastro-intestinal Diseases

Last week, I was in Bio Spring Europe and I met Alain Vicari, Calypso Biotech’s CEO: What is Calypso Biotech? Calypso Biotech discovers and develops antibody therapies for indications in gastro-intestinal diseases. The company tackles on niche diseases, with therapeutic antibodies against difficult targets. Calypso was founded in Geneva, in 2013, as a spin-off of […]

March 20, 2015 - 3 minutesmins - By Julie Lellouche

News and Trends 14 Mar 2015

Promising Collaboration Between Evotec and Second Genome

Evotec AG and Second Genome decided to collaborate in small molecule-based discovery and development activities for the treatment of microbiome-mediated diseases. The collaboration comprises the identification and optimisation of novel compounds as well as licence agreements for already existing assets developed by Evotec. Second Genome’s unique approach to identify and modulate microbiome-mediated pathways will be […]

March 14, 2015 - 2 minutesmins - By Julie Lellouche

News and Trends 22 Jan 2015

Novabiotics Tackles Antibiotic Resistance by Raising €6,5M Euros

NovaBiotics Ltd has raised €6,5M for priority clinical stage first-in-class antimicrobial therapeutics assets. The private placement with Woodford Investment Management LLP was arranged by Shore Capital as financial adviser and broker to the company. NovaBiotics is a clinical-stage biotechnology company focused on the design and development of first-in-class anti-infectives for difficult-to-treat, medically unmet diseases. NovaBiotics has spent more than 10 […]

January 22, 2015 - 2 minutesmins - By Julie Lellouche

News and Trends 19 Dec 2014

The French Leader in Insect Transformation Raised 5,5 Million Euros

Nine months after its first 1.8 million euros funding campaign, YNSECT, “The Insect Company”, a company specialized in insect biotechnology, has raised another 5.5 million euros. YNSECT is on its way to become a European and World leader in the insect field. The world is facing a major challenge: the food demand is expected to double by […]

December 19, 2014 - 2 minutesmins - By Julie Lellouche

News and Trends 16 Dec 2014

An Effective Renewed Partnership for Treatment of Gynecological Cancers

Curie-Cancer, the part responsible for developing Institut Curie’s industry partnership activities, and GamaMabs Pharma, a company specialized in the development of monoclonal antibodies for cancer, extended their partnership to develop the 3C23K antibody for the treatment of gynecological cancers. An initial partnership agreement was concluded in 2013 and the results of work on the 3C23K antibody were presented to the Ovarian […]

December 16, 2014 - 2 minutesmins - By Julie Lellouche

News and Trends 15 Dec 2014

Will there be a New Merck-Serono?

GeNeuro SA has signed a unique partnership with Servier. The French pharmaceutical giant have bought an option for €38M on the marketing rights outside the United States and Japan for a treatment against multiple sclerosis. Could GeNeuro become the next Merck-Serono? This amount will allow the Swiss company to continue the clinical development of this molecule. […]

December 15, 2014 - 2 minutesmins - By Julie Lellouche

News and Trends 11 Dec 2014

After Merck’s Big Deal, Pfizer Collaborates with iTeos Therapeutics for Cancer Treatments

iTeos Therapeutics SA enters in a strategic collaboration with Pfizer Inc where iTeos will license to Pfizer rights to iTeos’ pre-clinical compounds targeting the enzymes expressed in many cancers. Pfizer will be responsible for the development and commercialization of IDO1 and TDO2 drug candidates. It completes a previous deal with Merck a few weeks ago. Additionally, […]

December 11, 2014 - 2 minutesmins - By Julie Lellouche

News and Trends 10 Dec 2014

Promising Agreement Signed for Regenerative Medicine

Heraeus Medical signed an agreement with Locate Therapeutics to license the intellectual property surrounding the use of TAOS in orthopaedic applications and the inception of the first development program in this field. The agreement gives Heraeus Medical GmbH the rights to the future co-developed orthopaedic products as well as the processes involved in manufacturing the final product. […]

December 10, 2014 - 2 minutesmins - By Julie Lellouche

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us